Bolt Biotherapeutics Advances BDC-4182 ISAC to Cohort 4 with Initial Data Due Q3 2026

With $18.1 million in cash and a runway extending only into Q1 2027, Bolt Biotherapeutics is operating under conditions that will sharpen scrutiny of every manufacturing and clinical decision tied to BDC-4182, its first-in-class Boltbody ISAC targeting claudin 18.2 in gastric and gastroesophageal cancers. For CDMOs and contract manufacturing partners currently engaged or evaluating engagement with lean-capital oncology biotechs, the company's Q2 2026 results signal a compressed timeline to a data-driven inflection point.

The Phase 1/2 study is now dosing patients in Cohort 4 at 4.0 mg/kg, with step-up dosing adopted from the T-cell engager commercial playbook to manage tolerability at higher dose levels. BDC-4182 has been reported as well tolerated to date, with activity described as consistent with its immune-stimulating mechanism of action. Initial clinical data are expected to be disclosed alongside Q3 2026 financial results, positioning the readout as a near-term binary event for the program.

From a process and supply perspective, the ISAC construct presents a distinct manufacturing profile: a tumor-targeting antibody, a non-cleavable linker, and a proprietary immune stimulant designed to recruit and activate myeloid cells. That non-cleavable linker chemistry differentiates BDC-4182 from cytotoxic ADCs and carries its own conjugation and analytical characterization requirements under 21 CFR Part 211 and ICH Q10 quality system expectations. CDMOs supporting early-phase ISAC programs should anticipate that process validation timelines will need to align tightly with a sponsor's constrained capital position.

Financially, R&D expenses fell to $5.1 million in Q2 2026 from $7.5 million in Q2 2025, a reduction attributed primarily to restructuring-driven headcount reductions and lower overall research activity. G&A expenses similarly contracted to $2.4 million from $3.5 million. Collaboration revenue was negligible at $5,000 for the quarter, down from $1.8 million in the prior-year period, reflecting the wind-down of R&D collaboration performance obligations. The operating loss narrowed to $8.4 million from $9.2 million year-over-year.

The Q3 2026 clinical data release will determine whether Bolt can attract the partnership capital needed to extend operations beyond Q1 2027 and sustain the manufacturing and regulatory infrastructure required to advance BDC-4182 through dose escalation.

Source: Bolt Biotherapeutics, Inc. via GlobeNewswire, August 11, 2026.